We studied surveillance, incidence and outcome of viral infections in children undergoing allogeneic hematopoietic cell transplantation (HCT) in the main pediatric transplant units in Spain. We prospectively collected data from first year post-HCT in every consecutive allogeneic HCT performed during 3 years (N ¼ 215): first HCT ¼ 188 and second HCT ¼ 27; median age ¼ 6.6 years (0.1-20.7). Most patients had acute leukemia (N ¼ 137) and 135 recipients (63%) were CMV seropositive. A total of 46 patients underwent cord blood transplant, 133 patients underwent HCT from alternative donors (62%) and 101 patients received anti-thymocyte globulin. Observational time was completed in 137 patients, whereas the remaining 78 died after a median survival time of 99 days (3-352). CMV was monitored in all patients; adenovirus (ADV) and human herpesvirus 6 (HHV-6) were monitored in 101 and 33 patients, respectively. We found 145 viral infections in 103 patients: CMV (n ¼ 42), ADV (n ¼ 32), HHV-6 (n ¼ 7), polyomavirus (n ¼ 20), EBV (n ¼ 6), VZV (n ¼ 17) and others (n ¼ 8). CMV infection was significantly higher in seropositive patients (25 vs 7%) (P ¼ 0.02). Extensive chronic GVHD (cGVHD) was significantly associated with an increased rate of viral infections (12 of 16 patients with cGVHD had infections vs 91 of 199 without GVHD) (P ¼ 0.035). In total, 10 patients (4.6%) died of viral infections (CMV ¼ 5, ADV ¼ 3, respiratory ¼ 2). We found a high incidence of viral infection, but mortality was low.
We studied surveillance, incidence and outcome of viral infections in children undergoing allogeneic hematopoietic cell transplantation (HCT) in the main pediatric transplant units in Spain. We prospectively collected data from first year post-HCT in every consecutive allogeneic HCT performed during 3 years (N ¼ 215): first HCT ¼ 188 and second HCT ¼ 27; median age ¼ 6.6 years (0.1-20.7). Most patients had acute leukemia (N ¼ 137) and 135 recipients (63%) were CMV seropositive. A total of 46 patients underwent cord blood transplant, 133 patients underwent HCT from alternative donors (62%) and 101 patients received anti-thymocyte globulin. Observational time was completed in 137 patients, whereas the remaining 78 died after a median survival time of 99 days . CMV was monitored in all patients; adenovirus (ADV) and human herpesvirus 6 (HHV-6) were monitored in 101 and 33 patients, respectively. We found 145 viral infections in 103 patients: CMV (n ¼ 42), ADV (n ¼ 32), HHV-6 (n ¼ 7), polyomavirus (n ¼ 20), EBV (n ¼ 6), VZV (n ¼ 17) and others (n ¼ 8). CMV infection was significantly higher in seropositive patients (25 vs 7%) (P ¼ 0.02). Extensive chronic GVHD (cGVHD) was significantly associated with an increased rate of viral infections (12 of 16 patients with cGVHD had infections vs 91 of 199 without GVHD)
Introduction
Infectious diseases have been recognized as one of the main early complications after hematopoietic cell transplantation (HCT). 1 The incidence of viral infections has increased as transplantations with alternative donors (cord blood, HLA-mismatched and unrelated donors) and manipulation of the grafts have become more common. [2] [3] [4] [5] [6] [7] [8] The use of prophylactic or preemptive antiviral treatment against CMV and recurrent herpes simplex infections has become a well-established standardized practice. Nevertheless, in recent years, different viruses such as human herpesvirus 6 and 7 (HHV-6 and HHV-7), adenovirus (ADV) and other respiratory viruses are the causative agents of increased morbidity during post transplant immunocompromised status. Some studies have shown that, as it occurs in CMV infection, the early viral detection, mainly of ADV, could avoid a catastrophic outcome as new antiviral drugs are effective when treatment is started early, in the viral replication phase, before the viruses damage different tissues or organs. 4, 9 The aim of this study was to find out the incidence and outcome of viral infections in children undergoing HCT in different units belonging to GETMON (Grupo Espan˜ol de Transplante de Me´dula Ó sea en Nin˜os).
Materials and methods
We designed an observational prospective study focused to know our surveillance praxis, incidence and outcome of viral infection in children undergoing allogeneic HCT.
The study enrolled every consecutive patient transplanted in the main pediatric transplant units in Spain, during a 3-year period (January 2004 to December 2006). Autologous transplantation was not included.
Population data
We collected, as baseline patient's characteristics, main diagnosis and disease status before transplant, age and immunological status. Source of stem cells, type of donor, conditioning regimen and use of anti-thymocyte globulin (ATG), T-cell depletion (TCD) or any other manipulation of the graft were also registered. Acute GVHD (aGVHD) and chronic GVHD (cGVHD) according to the aGVHD Consensus Workshop (1995) 10 and classical (limited/extensive) cGVHD classification, hematopoietic reconstitution, chimerism and any incidence accounting during the first year after HCT were recorded too.
Viral surveillance and infections
Cytomegalovirus, EBV and HSV serostatus (IgM and IgG) of donors and recipients before transplantation were investigated.
Cytomegalovirus was studied in all patients by antigenemia, DNA detection or throat shell vial rapid culture. Quantitative PCR (viral load) was not included in this series. ADV was monitored by using either blood PCR DNA detection method or blood, throat-swab, stool or urine culture techniques. HHV-6 DNA was determined by PCR. Respiratory viruses were investigated by throat shell vial rapid culture only when it was considered suitable according to epidemiological data.
Cytomegalovirus infection was defined as positive antigenemia (one determination showing 410 infected cells) or positive blood DNA detection (two consecutive samples). A single positive culture obtained from a throat swab was considered suspicious and required to be confirmed by another method or using another sample. ADV infection was diagnosed when viral DNA was found in blood (positive PCR in two consecutive samples) or in the presence of gastrointestinal, urinary or respiratory symptoms and DNA PCR-positive or culture-positive result from stool, urine or throat-swab samples respectively. A positive finding of HHV-6 DNA (PCR) in blood, BM or cerebrospinal fluid was considered infection. Antiviral prophylactic regimen used and all documented viral infections during the first year post transplantation (observational time designed for this study) were recorded.
Statistical analysis
Data were collected with Microsoft Access 2002 (Microsoft) and analyzed with SPSS version 12.0 (www.spss.com). The analysis was carried out when all the surviving patients reached a post transplantation follow-up longer than 1 year.
Univariate analysis (w 2 -test, Fisher's tests) were used to find out the association between some factors and viral infections. Odds ratio was calculated to explore the factors that determined an increased risk of infections. Multivariate test was considered to be not applicable after analyzing the results.
Results
During the recruitment period (January 2004 to December 2006), 215 transplants were performed (first transplant: 188 and second transplant: 27) in eight hospitals. Table 1 shows baseline characteristics of patients. The most frequent underlying disease was acute leukemia, although 58 children with nonmalignancies were also included in this study.
Patient and transplantation characteristics
Transplantation characteristics are listed in Table 2 . Most patients received progenitor cells from BM or peripheral blood. Nevertheless, in 21% of patients (N ¼ 46), the source of cells was cord blood.
Only 82 patients had a related HLA-identical donor; consequently, 133 (62%) underwent transplant from Viral surveillance and prophylaxis Serological status of donors and patients before transplantation was analyzed: 135 patients (63%) and 128 donors (59%) were CMV positive (IgG). IgG positivity to EBV was found in 136 recipients (63%) and 77 donors (36%).
In total, 137 out of 215 transplanted patients survived more than 1 year (the total chosen surveillance period in our study). The remaining 78 had a median survival time of 99 days (range: 3-352).
Cytomegalovirus was weekly or twice weekly investigated in 211 patients until day þ 100 and monthly thereafter. Detection of antigenemia was carried out in 141 patients (weekly: 137 and twice a week: 4 patients), DNA PCR in 35 patients and a combination of methods (antigenemia, PCR DNA and rapid culture) in the remaining patients. ADV was monitored in 101 patients (47%) by means of blood, throat-swab or urine culture 
Viral infections
A total of 145 infections were recorded in 103 patients (48%) who had at least one documented viral infection (Table 3) . CMV was the most prevalent (n ¼ 42) followed by ADV (n ¼ 32). With the exception of VZV and respiratory virus, all infections were documented during the first 6 months post-HCT and some cases very early in the post transplant period. All patients with CMV infection (n ¼ 42) and 28 of 32 cases with ADV infection received preemptive treatment, and fortunately, only eight and six cases, respectively developed disease. Treatment of six children showing EBV replication consisted of reduction of immunosuppression , rituximab and/or foscarnet, and only two developed a lymphoproliferative disorder. HHV-6 infection was diagnosed in seven patients in the context of a compatible clinical picture (encephalitis, pneumonia, hepatitis, rash and fever); all received treatment (ganciclovir ± other: 4 and foscarnet: 3) and none died. Two patients with Polyomavirus had no symptoms and 18 had hemorrhagic cystitis. Only eight received antiviral drugs (cidofovir: 6 and foscarnet: 2). Three more patients had hemorrhagic cystitis due to ADV infection (N ¼ 2) or CMV (N ¼ 1). Reactivation of VZV virus caused chickenpox in four children and herpes zoster in the remainder 13 infected patients without Only 10 patients in this series died because of their viral infections (Table 3) , which represents a mortality rate of 9.7% in the cohort of 103 infected patients. When we analyzed the overall group, the mortality rate due to viral infection was 4.6%.
Factors associated with viral infections
We separately analyzed the incidence of viral infection in the small group of second transplants: 10 out of 27 patients receiving a second transplant (37%) had some viral infection (CMV ¼ 5, respiratory virus ¼ 1, ADV ¼ 0 and other virus ¼ 4), whereas in the group of first transplantations, the infection rate was 49% (P ¼ n.s). Consequently, we studied all transplants as a single group to analyze the influence of remaining factors.
Serological status of the recipient before transplantation highly correlated with the incidence of CMV infection. We found a 3.5-fold increased risk (1.4-8.4) of infection in CMV seropositive patients: 33 out of 135 IgG CMVpositive patients had CMV infections (25%) vs 5 of 70 (7%) in the seronegative cohort (P ¼ 0.02). Table 4 summarizes donor-recipient couples's serostatus concerning different viruses and represents the incidence of CMV infection in different donor-recipient couples's situations regarding their serological status. We found a significantly higher incidence in seropositive recipients transplanted from negative donor (32%) (P ¼ 0.03; odds ratio ¼ 1.9 (1.08-3.3)). When both donor and recipient were positive, the incidence of CMV reactivation was higher than that observed in the remainder group, but the difference did not reach statistical significance (P ¼ 0.07).
Among other factors that might have been associated with development of viral infections, we observed a trend toward a higher incidence in patients transplanted with alternative donors when compared with those transplanted with HLA-identical family donors (51 vs 43%, P ¼ 0.22) (Table 5) , as was in patients receiving ATG during conditioning regimen (53 vs 43%, P ¼ 0.12), but these differences did not reach statistical significance. A total of 21 out of 46 cord blood recipients (46%) had any viral infection, which did not differ from 82 out of 169 BM or peripheral blood recipients (48%). TCD of the harvest did not show any influence over the viral infection rate in our series: 28 of 56 TCD recipients had any infection (50%) vs 75 of 159 receiving unmanipulated grafts (47%) (P ¼ 0.7; odds ratio ¼ 1.06) ( Table 5 ). Concerning GVHD, we found 16 viral infections in 34 children with grade III or IV aGVHD (53%) and 87 among 185 without GVHD (47%) (P ¼ 0.5); however, extensive cGVHD significantly correlated to a higher viral infection rate: 12 of 16 with GVHD (75%) had viral infections vs 91 of 199 without GVHD (45%) (P ¼ 0.035; odds ratio ¼ 3.2 (1.1-9.7)).
Discussion
This is a prospective observational study designed to know the epidemiology, treatment and outcome of viral infections in the setting of children undergoing HCT in our ambit (Pediatric Transplant Units in Spain).
Monitoring CMV is a well-recognized practice. Different techniques have been developed, although quantitative PCR (viral load) of the plasma specimens is the gold standard nowadays. Early detection of CMV replication and introduction of preemptive antiviral treatment have proven to be effective weapons for controlling infections before injuring tissues or organs. 11 With the exception of four patients, CMV was monitored in all the patients reported here. However, PCR viral load, the mostly used method in our institutions today, was still not introduced at the time when our last patient was enrolled in this study.
Recently, an increase in other viral infections has been observed. [1] [2] [3] [4] [5] [6] [7] [8] ADV emerged as an important pathogen in children, and different studies showed that viral dissemination determines a dismal outcome. Consequently, precocity to identify virus replication and to start antiviral treatment is crucial to avoid a fatal outcome. 4, 12 For this reason, ADV monitoring has been recommended as a general practice. During this study period, it was included as a routine procedure only in four participating hospitals, which explains that o50% of the patients were monitored. Table 5 Ex-vivo T-cell depletion (TCD) and infected patients: distribution according to donor's type and source of stem cells. (9) 2 (10) 84 (39) 133 (62) Abbreviations: + ¼ positive; neg ¼ negative; D ¼ donor; R ¼ recipient.
Post-SCT viral infections in children
In our experience, quantitative PCR or other culture techniques are valuable tools to identify patients at risk for viral invasive disease, according to previously reported studies. 12, 13 Several reports appointed a high incidence of HHV-6 DNA positivity, mainly in children, when plasma load was routinely measured. 14, 15 Only 33 patients enrolled in this study (15%) had HHV-6 DNA routinely monitored, and seven out of them (21%) showed viral reactivation. Our series is too small though to reach significant conclusions about HHV-6 infection.
Regarding EBV, it has also been reported that routine EBV surveillance and preemptive treatment when sustained viral DNA levels are found, can avoid the development of a post transplant lymphoproliferative disorder. 16 In our series, six patients had EBV DNA positivity and only two developed a post transplant lymphoproliferative disorder.
In our experience, with the exception of VZV and respiratory virus, all infections were documented during the first 6 months post-HCT and sometimes, infections were detected very early in the post transplant period. A Safdar et al. 17 reported that beyond day þ 100 after cord blood transfer, CMV and VZV infections occurred only in children with cGVHD. Only 24 patients in our series had cGVHD, which could explain the low incidence of infections beyond 6 months post transplantation.
Despite the high mortality attributable to viral infections, we found a low mortality rate, possibly because a high percentage of patients were preemptively treated and few children developed disease. The early recognition of different viruses and the introduction of new antiviral drugs have lead to improvements in the previous dismal prognosis. Cidofovir has proven to be an effective treatment in ADV and HHV-6 infections, with acceptable tolerance in children, 12, 18 although other measures, such as a prompt withdrawal of immunosuppression and lymphocyte recovery, have shown to be determinants to reduce the mortality rate. 4, 19, 20 Concerning risk factors that can potentially increase the likelihood to develop viral infections, we found recipient serostatus to be the dominant risk factor for CMV infection, according to other published series. 21, 22 Morbidity related to a high incidence of infections has been one of the limitations to the use of cord blood as source of cells. Benjamin et al., 23 in a retrospective study including 485 children, observed that after 30 days from TPH, children who received unrelated cord blood and matched unrelated donor transplantation were at much higher risk of infection than were patients who received matched sibling or haploidentical transplantation; specifically with regard to viruses, patients who received unrelated cord blood or unrelated donor were at higher risk of ADV but not CMV. However, we did not find a significant increase of viral infections in the group of unrelated cord blood recipients when compared with BM or peripheral blood recipients, a result that agrees with other reported data. 24, 25 It has been communicated that in vivo (ATG) and ex vivo TCD can contribute to increased infection susceptibility. 2 Nevertheless, in the series reported here, although the incidence was higher when alternative donor, cord blood transfer, ATG or TCD were used, the difference did not reach significance. Only extensive cGVHD was significantly associated with a higher viral infection rate, according to the data previously reported in children. 25, 26 We believe that this lack of significance could probably be explained by insufficient number of patients.
In conclusion, we found a high viral infection rate during the first year post transplantation. However, a low percentage of patients developed the disease, and their outcome was acceptable with a low mortality rate. With the exception of cGVHD, we did not find any factor significantly associated with an increased incidence. According to both our results and reviewed literature, we would like to remark that a closed surveillance of viral plasma load and a prompt treatment are indispensable measures to reduce the fatal outcome of this common complication, mainly in children.
